Kristina, living with ALS
PHOENIX (NCT05021536) is a Phase 3, randomized, placebo-controlled trial in approximately 65 sites across the U.S. and Europe evaluating the safety and efficacy of sodium phenylbutyrate and taurursodiol (also known as ursodoxicoltaurine) in people living with amyotrophic lateral sclerosis (ALS). Recruitment for this trial is closed in the U.S. and ongoing in Europe.
At Amylyx, we are relentlessly driven by a commitment to those living with neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create more moments for the neurodegenerative community.
Our innovative approach to developing transformative therapeutics has far-reaching potential to improve the management of multiple neurodegenerative diseases. Learn more about our clinical trials.
An error has occurred. Please refresh the page and retry.
If you’d like to receive updates about what’s happening at Amylyx, click subscribe.